Phase Ib study with expansion of ibrutinib, lenalidomide, and rituximab in patients with relapsed/refractory central nervous system lymphoma

R2I was tolerated well with high response rates and a short time to best respond. Median PFS was limited but 1/3 of patients had durable responses >12 months. This trial was registered at www.clinicaltrials.gov (NCT03703167).

Authors

Institutions

Publication Details

Journal
Neuro-Oncology
Published
2025-04-22
DOI
https://doi.org/10.1093/neuonc/noaf104
Citations
2
Primary Topic
CNS Lymphoma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
2.78

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Phase Ib study with expansion of ibrutinib, lenalidomide, and rituximab in patients with relapsed/refractory central nervous system lymphoma

Jasmine H. Francis, Katherine S. Panageas, Lisa Marie DeAngelis, Rachna Malani et al.
2 citations
Neuro-Oncology
CNS Lymphoma Diagnosis and Treatment
2.78
article

Phase Ib study with expansion of ibrutinib, lenalidomide, and rituximab in patients with relapsed/refractory central nervous system lymphoma

Jasmine H. Francis, Katherine S. Panageas, Lisa Marie DeAngelis, Rachna Malani, Christian Grommes, Elena Pentsova, Robert J. Young, Joe Sammy Mendez, Anna F. Piotrowski, Lauren R. Schaff, Ingo K. Mellinghoff, Igor T. Gavrilovic, Sarah Tang, Vaios Hatzoglou, Anne S. Reiner, Thomas Kaley, Andrew Lin, Laura Quinn, Craig Nolan, Venissala Wongchai, Ashley Gonzalez, Juli T. Madzsar, Laura Breakey, Laleh Emadi-Paramkouhi
article en
2 citations

Abstract

R2I was tolerated well with high response rates and a short time to best respond. Median PFS was limited but 1/3 of patients had durable responses >12 months. This trial was registered at www.clinicaltrials.gov (NCT03703167).

Neuro-OncologyVol. 27(8)
Memorial Sloan Kettering Cancer Center (US), Cornell University (US), University of Utah (US), Huntsman Cancer Institute (US)
National Cancer Institute, National Institute of Neurological Disorders and Stroke
Good health and well-being
Openalex Percentile: Top 11%
CNS Lymphoma Diagnosis and Treatment
2.78
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.